Features of the gut microbiota metabolism and their relationship with the parameters of the lipid profile in patients with type 2 diabetes mellitus receiving tableted hypoglycemic therapy
- 3 May 2026
- journal article
- Published by Focus Endocrinology in FOCUS. Endocrinology
- Vol. 7 (1) , 14-23
Abstract
Introduction. Gut microbiota (GM) metabolism in patients with type 2 diabetes mellitus (T2DM) has a number of features, including changes in the functional characteristics of microorganisms and, as a result, changes in the levels of the main metabolites of GM – short-chain fatty acids (SCFA). The purpose of the study. To investigate the features of the SCFA in patients with T2DM receiving innovative hypoglycemic therapy combined with metformin. Materials and methods. The study included 80 patients with T2DM aged 45–60 years, with the duration of the disease to 5 years, HbA1c did not exceed 7.5 %, BMI was 27–35 kg/m 2 . All patients received metformin and SGLT-2 inhibitors or metformin and DPP-4 inhibitors. Results. The median age of the patients was 55 [52-57] years, and the median duration of T2DM was 2 [1-4] years. The average BMI in the group was 31.22 ± 2.42 (95 % CI: 30.68–31.76) kg/m 2 . The average HbA1c level – 6.16 ± 0.79 (95 % CI: 5.98–6.33) %. A significant decrease in the level of the amount of SCFA (3,664 [2,053–7,014] mg/g) was revealed compared with the people without T2DM (10.5 ± 1.5 mg/g). The absolute concentrations of acetic, propionic, and butyric acids are also almost threefold reduced (1.93 [0.95–3.99] mg/g, 0.82 [0.39–1.58] mg/g, 0.55 [0.30–1.31] mg/g). The anaerobic index was shifted towards sharply negative values and amounted to -0.76 ± 0.25 (95 % CI: from -0.81 to -0.70). There were no statistically significant differences between the treatment groups of patients. Conclusions. The data obtained highlight the unresolved problem of decompensation of the microbiotic link in the pathogenesis of T2DM.Keywords
This publication has 20 references indexed in Scilit:
- The interplay between gut microbiota, short-chain fatty acids, and implications for host health and diseaseGut Microbes, 2024
- Pathogenetic aspects of the development and treatment of antibiotic-associated diarrhea: the choice of a synbiotic from the standpoint of evidence-based medicineMeditsinskiy sovet = Medical Council, 2023
- Gut microbiota-derived butyrate regulates gut mucus barrier repair by activating the macrophage/WNT/ERK signaling pathwayClinical Science, 2022
- Gut Microbial Dysbiosis Associated with Type 2 Diabetes Aggravates Acute Ischemic StrokemSystems, 2021
- Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and diseaseCell Metabolism, 2021
- Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?EBioMedicine, 2021
- The role of short-chain fatty acids in intestinal barrier function, inflammation, oxidative stress, and colonic carcinogenesisPharmacological Research, 2021
- Use of breath testing in gastrointestinal disordersHERALD of North-Western State Medical University named after I.I. Mechnikov, 2020
- SCFA: mechanisms and functional importance in the gutProceedings of the Nutrition Society, 2020
- Dietary short-chain fatty acid intake improves the hepatic metabolic condition via FFAR3Scientific Reports, 2019